“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors

Several evidences have shown that BRCA mutations increased tumor-cells sensitivity to PARP inhibitors by synthetic lethality leading to an accelerated development of several compounds targeting the PARP enzymes system as anticancer agents for clinical setting. Most of such compounds have been invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Incorvaia, Lorena, Passiglia, Francesc, Rizzo, Sergio, Galvano, Antonio, Listȶ, Angela, Barraco, Nadia, Maragliano, Rossella, Calò, Valentina, Natoli, Clara, Ciaccio, Marcello, Bazan, Viviana, Russo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410353/
https://www.ncbi.nlm.nih.gov/pubmed/28055979
http://dx.doi.org/10.18632/oncotarget.14409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410353/
https://www.ncbi.nlm.nih.gov/pubmed/28055979
http://dx.doi.org/10.18632/oncotarget.14409

Ejemplares similares